Hence, adverse health risk factors in mothers receiving pharmaceutical treatment could have contributed to the finding that OGDM‐Metformin and OGDM‐Insulin, but not OGDM‐Lifestyle (as shown in additional analyses), had faster growth than No‐GDM. This evidence concerns the gene INS and gestational diabetes.